Tradeshow Apr 08, 2022 - Apr 14, 2022 New Orleans, LA | Booth #2018 Join us at American Association for Cancer Research (AACR) Annual Meeting 2022! Let’s talk about Thermo Fisher’s molecular technologies and workflows are revolutionizing our view of cancer. ...
Join us at American Association for Cancer Research (AACR) Annual Meeting 2022! Let’s talk about Thermo Fisher’s molecular technologies and workflows are revolutionizing our view of cancer. We'll share the latest innovations in next generation cellular analysis, precise tumor profiling with digita...
Nonmember individuals interested in joining the AACR and sponsoring an abstract for AACR Annual Meeting 2022 must submit an application for membership no later than November 12, 2021. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an a...
Nonmember individuals interested in joining the AACR and sponsoring an abstract for AACR Annual Meeting 2022 must submit an application for membership no later than November 12, 2021. Individuals interested in joining the AACR and sponsoring a clinical trial or late-breaking abstract must submit an a...
美国癌症研究学会 (AACR) 成立于 1907 年,是成立最早、规模最大的癌症研究学会之一,致力于进行全面、创新和高水准癌症研究。AACR 以其卓越的声誉吸引着世界的研究人员,促进了癌症研究领域科学家之间的思想交流。 2022 年 AACR 年会将于 2022 年 4 月 8-13 日在美国路易斯
美国癌症研究学会 (AACR) 成立于 1907 年,是成立最早、规模最大的癌症研究学会之一,致力于进行全面、创新和高水准癌症研究。AACR 以其卓越的声誉吸引着世界的研究人员,促进了癌症研究领域科学家之间的思想交流。 2022 年 AACR 年会将于 2022 年 4 月 8-13 日在美国路易斯...
2022年4月4日,道尔生物将在美国路易斯安那州新奥尔良市举办的2022年美国癌症研究协会年会(AACR Meeting 2022)上以现场墙报形式(Poster Presentation)公布其基于SMART-VHHBody平台技术自主研发的靶向CLDN18.2单域抗体DR30303的临床前关键研究数据。 美国癌症研究学会(AACR)年会是全球历史最为悠久、最具权威性的肿瘤研究学术...
2022年4月4日,道尔生物将在美国路易斯安那州新奥尔良市举办的2022年美国癌症研究协会年会(AACR Meeting 2022)上以现场墙报形式(Poster Presentation)公布其基于SMART-VHHBody平台技术自主研发的靶向CLDN18.2单域抗体DR30303的临床前关键研究数据。 美国癌症研究学会(AACR)年会是全球历史最为悠久、最具权威性的肿瘤研究学术...
American Association for Cancer Research (AACR) Annual Meeting 2022 April 08 - 13, 2022New Orleans, LA and Virtual/Online Preop Nivolumab Plus Chemo 'a Quantum Leap' in NSCLC Therapy Medscape Medical News, April 12, 2022 'Truly Impressive' Responses in Lymphoma With Novel Cell Therapy...
open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC). Presented at: AACR A...